Literature DB >> 30139748

Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy.

Kenneth M Estrellas1,2, Liam Chung2,3, Lindsay A Cheu4, Kaitlyn Sadtler5,6, Shoumyo Majumdar2, Jyothi Mula7, Matthew T Wolf2,3, Jennifer H Elisseeff8,3, Kathryn R Wagner9,10.   

Abstract

Recent studies have reported that the immune system significantly mediates skeletal muscle repair and regeneration. Additionally, biological scaffolds have been shown to play a role in polarizing the immune microenvironment toward pro-myogenic outcomes. Moreover, myostatin inhibitors are known to promote muscle regeneration and ameliorate fibrosis in animal models of Duchenne muscular dystrophy (DMD), a human disease characterized by chronic muscle degeneration. Biological scaffolds and myostatin inhibition can potentially influence immune-mediated regeneration in the dystrophic environment, but have not been evaluated together. Toward this end, here we created an injectable biological scaffold composed of hyaluronic acid and processed skeletal muscle extracellular matrix. This material formed a cytocompatible hydrogel at physiological temperatures in vitro When injected subfascially above the tibialis anterior muscles of both WT and dystrophic mdx-5Cv mice, a murine model of DMD, the hydrogel spreads across the entire muscle before completely degrading at 3 weeks in vivo We found that the hydrogel is associated with CD206+ pro-regenerative macrophage polarization and elevated anti-inflammatory cytokine expression in both WT and dystrophic mice. Co-injection of both hydrogel and myostatin inhibitor significantly increased FoxP3+ regulatory T cell modulation and Foxp3 gene expression in the scaffold immune microenvironment. Finally, delivery of myostatin inhibitor with the hydrogel increased its bioactivity in vivo, and transplantation of immortalized human myoblasts with the hydrogel promoted their survival in vivo This study identifies a key role for biological scaffolds and myostatin inhibitors in modulating a pro-regenerative immune microenvironment in dystrophic muscle.

Entities:  

Keywords:  bioengineering; biomaterials; cytokine; drug delivery; dystrophin; extracellular matrix; hydrogel; immunology; mdx; muscle; muscle regeneration; muscular dystrophy; myostatin; stem cells

Mesh:

Substances:

Year:  2018        PMID: 30139748      PMCID: PMC6177591          DOI: 10.1074/jbc.RA118.004417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Evidence-based path to newborn screening for Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Chris Shilling; Nancy D Leslie; Kevin M Flanigan; Roula al-Dahhak; Julie Gastier-Foster; Kelley Kneile; Diane M Dunn; Brett Duval; Alexander Aoyagi; Cindy Hamil; Maha Mahmoud; Kandice Roush; Lauren Bird; Chelsea Rankin; Heather Lilly; Natalie Street; Ram Chandrasekar; Robert B Weiss
Journal:  Ann Neurol       Date:  2012-03       Impact factor: 10.422

2.  GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding.

Authors:  R S Thies; T Chen; M V Davies; K N Tomkinson; A A Pearson; Q A Shakey; N M Wolfman
Journal:  Growth Factors       Date:  2001       Impact factor: 2.511

3.  mdx(⁵cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice.

Authors:  Nicholas Beastrom; Haiyan Lu; Allison Macke; Benjamin D Canan; Eric K Johnson; Christopher M Penton; Brian K Kaspar; Louise R Rodino-Klapac; Lan Zhou; Paul M L Janssen; Federica Montanaro
Journal:  Am J Pathol       Date:  2011-09-03       Impact factor: 4.307

4.  Interferon-γ resets muscle cell fate by stimulating the sequential recruitment of JARID2 and PRC2 to promoters to repress myogenesis.

Authors:  Priya Londhe; Judith K Davie
Journal:  Sci Signal       Date:  2013-12-10       Impact factor: 8.192

5.  Biomimetic Material-Assisted Delivery of Human Embryonic Stem Cell Derivatives for Enhanced In Vivo Survival and Engraftment.

Authors:  Harsha Kabra; Yongsung Hwang; Han Liang Lim; Mrityunjoy Kar; Gaurav Arya; Shyni Varghese
Journal:  ACS Biomater Sci Eng       Date:  2015-01-12

6.  Cardiac-Derived Extracellular Matrix Enhances Cardiogenic Properties of Human Cardiac Progenitor Cells.

Authors:  Roberto Gaetani; Christopher Yin; Neha Srikumar; Rebecca Braden; Pieter A Doevendans; Joost P G Sluijter; Karen L Christman
Journal:  Cell Transplant       Date:  2015-11-16       Impact factor: 4.064

7.  Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice.

Authors:  Berno Dankbar; Michelle Fennen; Daniela Brunert; Silvia Hayer; Svetlana Frank; Corinna Wehmeyer; Denise Beckmann; Peter Paruzel; Jessica Bertrand; Kurt Redlich; Christina Koers-Wunrau; Athanasios Stratis; Adelheid Korb-Pap; Thomas Pap
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

8.  TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.

Authors:  Daniela Palacios; Chiara Mozzetta; Silvia Consalvi; Giuseppina Caretti; Valentina Saccone; Valentina Proserpio; Victor E Marquez; Sergio Valente; Antonello Mai; Sonia V Forcales; Vittorio Sartorelli; Pier Lorenzo Puri
Journal:  Cell Stem Cell       Date:  2010-10-08       Impact factor: 24.633

9.  The immune system in Duchenne muscular dystrophy: Friend or foe.

Authors:  S Armando Villalta; Amy S Rosenberg; Jeffrey A Bluestone
Journal:  Rare Dis       Date:  2015-02-23

10.  A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.

Authors:  Michael St Andre; Mark Johnson; Prashant N Bansal; Jeremy Wellen; Andrew Robertson; Alan Opsahl; Peter M Burch; Peter Bialek; Carl Morris; Jane Owens
Journal:  Skelet Muscle       Date:  2017-11-09       Impact factor: 4.912

View more
  2 in total

1.  Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice.

Authors:  Russell G Rogers; Mario Fournier; Lizbeth Sanchez; Ahmed G Ibrahim; Mark A Aminzadeh; Michael I Lewis; Eduardo Marbán
Journal:  JCI Insight       Date:  2019-04-04

Review 2.  "The Social Network" and Muscular Dystrophies: The Lesson Learnt about the Niche Environment as a Target for Therapeutic Strategies.

Authors:  Ornella Cappellari; Paola Mantuano; Annamaria De Luca
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.